Amisulpride decreases tau protein hyperphosphorylation in the brain of OXYS rats
CONCLUSION: Thus, we propose amisulpride to have therapeutic potential against AD and that it can be the most effective in the early stages of the disease. We found that chronic administration of amisulpride could reduce pathological tau hyperphosphorylation while reducing anxiety.PMID:37641989 | DOI:10.2174/1567205020666230828144651 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Camilla A Molobekova Elena M Kondaurova Tatiana V Ilchibaeva Alexander Ya Rodnyy Natalia A Stefanova Nataliya G Kolosova Vladimir S Naumenko Source Type: research
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin
Curr Alzheimer Res. 2023 Aug 25. doi: 10.2174/1567205020666230825124922. Online ahead of print.ABSTRACTAlzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer's disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved by the FDA for Parkinson's psychosis. It is predicted that pimavanserin, a new antipsychotic, will fill an important gap in t...
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Faruk Kurhan Mustafa Ak ın Source Type: research
Amisulpride decreases tau protein hyperphosphorylation in the brain of OXYS rats
CONCLUSION: Thus, we propose amisulpride to have therapeutic potential against AD and that it can be the most effective in the early stages of the disease. We found that chronic administration of amisulpride could reduce pathological tau hyperphosphorylation while reducing anxiety.PMID:37641989 | DOI:10.2174/1567205020666230828144651 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Camilla A Molobekova Elena M Kondaurova Tatiana V Ilchibaeva Alexander Ya Rodnyy Natalia A Stefanova Nataliya G Kolosova Vladimir S Naumenko Source Type: research
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin
Curr Alzheimer Res. 2023 Aug 25. doi: 10.2174/1567205020666230825124922. Online ahead of print.ABSTRACTAlzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer's disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved by the FDA for Parkinson's psychosis. It is predicted that pimavanserin, a new antipsychotic, will fill an important gap in t...
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Faruk Kurhan Mustafa Ak ın Source Type: research
Amisulpride decreases tau protein hyperphosphorylation in the brain of OXYS rats
CONCLUSION: Thus, we propose amisulpride to have therapeutic potential against AD and that it can be the most effective in the early stages of the disease. We found that chronic administration of amisulpride could reduce pathological tau hyperphosphorylation while reducing anxiety.PMID:37641989 | DOI:10.2174/1567205020666230828144651 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Camilla A Molobekova Elena M Kondaurova Tatiana V Ilchibaeva Alexander Ya Rodnyy Natalia A Stefanova Nataliya G Kolosova Vladimir S Naumenko Source Type: research
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin
Curr Alzheimer Res. 2023 Aug 25. doi: 10.2174/1567205020666230825124922. Online ahead of print.ABSTRACTAlzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer's disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved by the FDA for Parkinson's psychosis. It is predicted that pimavanserin, a new antipsychotic, will fill an important gap in t...
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Faruk Kurhan Mustafa Ak ın Source Type: research
Amisulpride decreases tau protein hyperphosphorylation in the brain of OXYS rats
CONCLUSION: Thus, we propose amisulpride to have therapeutic potential against AD and that it can be the most effective in the early stages of the disease. We found that chronic administration of amisulpride could reduce pathological tau hyperphosphorylation while reducing anxiety.PMID:37641989 | DOI:10.2174/1567205020666230828144651 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Camilla A Molobekova Elena M Kondaurova Tatiana V Ilchibaeva Alexander Ya Rodnyy Natalia A Stefanova Nataliya G Kolosova Vladimir S Naumenko Source Type: research
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin
Curr Alzheimer Res. 2023 Aug 25. doi: 10.2174/1567205020666230825124922. Online ahead of print.ABSTRACTAlzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer's disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved by the FDA for Parkinson's psychosis. It is predicted that pimavanserin, a new antipsychotic, will fill an important gap in t...
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Faruk Kurhan Mustafa Ak ın Source Type: research
Amisulpride decreases tau protein hyperphosphorylation in the brain of OXYS rats
CONCLUSION: Thus, we propose amisulpride to have therapeutic potential against AD and that it can be the most effective in the early stages of the disease. We found that chronic administration of amisulpride could reduce pathological tau hyperphosphorylation while reducing anxiety.PMID:37641989 | DOI:10.2174/1567205020666230828144651 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Camilla A Molobekova Elena M Kondaurova Tatiana V Ilchibaeva Alexander Ya Rodnyy Natalia A Stefanova Nataliya G Kolosova Vladimir S Naumenko Source Type: research
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin
Curr Alzheimer Res. 2023 Aug 25. doi: 10.2174/1567205020666230825124922. Online ahead of print.ABSTRACTAlzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer's disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved by the FDA for Parkinson's psychosis. It is predicted that pimavanserin, a new antipsychotic, will fill an important gap in t...
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Faruk Kurhan Mustafa Ak ın Source Type: research
Amisulpride decreases tau protein hyperphosphorylation in the brain of OXYS rats
CONCLUSION: Thus, we propose amisulpride to have therapeutic potential against AD and that it can be the most effective in the early stages of the disease. We found that chronic administration of amisulpride could reduce pathological tau hyperphosphorylation while reducing anxiety.PMID:37641989 | DOI:10.2174/1567205020666230828144651 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Camilla A Molobekova Elena M Kondaurova Tatiana V Ilchibaeva Alexander Ya Rodnyy Natalia A Stefanova Nataliya G Kolosova Vladimir S Naumenko Source Type: research
A New Hope in Alzheimer's Disease Psychosis: Pimavanserin
Curr Alzheimer Res. 2023 Aug 25. doi: 10.2174/1567205020666230825124922. Online ahead of print.ABSTRACTAlzheimer's disease (AD) ranks first among the causes of dementia worldwide. AD can develop a psychotic manifest at a significant rate. AD prognosis worsens by added psychosis clinic. There is no treatment approved by the United States Food and Drug Administration (FDA) among antipsychotics for Alzheimer's disease Psychosis (ADP). However, pimavanserine, an atypical antipsychotic, has been approved by the FDA for Parkinson's psychosis. It is predicted that pimavanserin, a new antipsychotic, will fill an important gap in t...
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Faruk Kurhan Mustafa Ak ın Source Type: research
Amisulpride decreases tau protein hyperphosphorylation in the brain of OXYS rats
CONCLUSION: Thus, we propose amisulpride to have therapeutic potential against AD and that it can be the most effective in the early stages of the disease. We found that chronic administration of amisulpride could reduce pathological tau hyperphosphorylation while reducing anxiety.PMID:37641989 | DOI:10.2174/1567205020666230828144651 (Source: Current Alzheimer Research)
Source: Current Alzheimer Research - August 29, 2023 Category: Neurology Authors: Camilla A Molobekova Elena M Kondaurova Tatiana V Ilchibaeva Alexander Ya Rodnyy Natalia A Stefanova Nataliya G Kolosova Vladimir S Naumenko Source Type: research
Alterations in Peripheral Metabolites as Key Actors in Alzheimer's Disease
Curr Alzheimer Res. 2023 Aug 25. doi: 10.2174/1567205020666230825091147. Online ahead of print.ABSTRACTGrowing evidence supports that Alzheimer's disease (AD) could be regarded as a metabolic disease, accompanying central and peripheral metabolic disturbance. Nowadays, exploring novel and potentially alternative hallmarks for AD is needed. Peripheral metabolites based on blood and gut may provide new biochemical insights about disease mechanisms. These metabolites can influence brain energy homeostasis, maintain gut mucosal integrity, and regulate the host immune system, which may further play a key role in modulating the ...
Source: Current Alzheimer Research - August 25, 2023 Category: Neurology Authors: Can Sheng Xu Chu Yan He Qingqing Ding Shulei Jia Qiguang Shi Ran Sun Li Song Wenying Du Yuan Liang Nian Chen Yan Yang Xiaoni Wang Source Type: research
Alterations in Peripheral Metabolites as Key Actors in Alzheimer's Disease
Curr Alzheimer Res. 2023 Aug 25. doi: 10.2174/1567205020666230825091147. Online ahead of print.ABSTRACTGrowing evidence supports that Alzheimer's disease (AD) could be regarded as a metabolic disease, accompanying central and peripheral metabolic disturbance. Nowadays, exploring novel and potentially alternative hallmarks for AD is needed. Peripheral metabolites based on blood and gut may provide new biochemical insights about disease mechanisms. These metabolites can influence brain energy homeostasis, maintain gut mucosal integrity, and regulate the host immune system, which may further play a key role in modulating the ...
Source: Current Alzheimer Research - August 25, 2023 Category: Neurology Authors: Can Sheng Xu Chu Yan He Qingqing Ding Shulei Jia Qiguang Shi Ran Sun Li Song Wenying Du Yuan Liang Nian Chen Yan Yang Xiaoni Wang Source Type: research
